Dr Arvind Parmar

Position: Imaging Physiologist
Phone: +61 (0)2 9717 9602 or +61 (0)2 9114 4221
Email: arvind.parmar@ansto.gov.au  

 
Role at ANSTO

Arvind’s primary responsibility at ANSTO is to apply in vivo, ex vivo and in vitro techniques to the investigation of diseases (onset, progression, regression) in preclinical models for the purpose of improving diagnostic and therapeutic tools in various clinical fields mainly cancer, CVS and metabolic disorders using multi-modality pre-clinical imaging systems such as PET/CT and SPECT/CT.

He also acts as a deputy Quality co-ordinator within ANSTO LifeSciences.

Background

After working for 2 years at AstraZeneca, UK, as imaging scientist Arvind has joined ANSTOLifeSciences in May 2011. His main expertise is in vivo small animal imaging.

He has worked for over a decade on various pharmacological disease models mainly on cancer, infectious diseases and inflammation. He did his Master of Pharmacy in Pharmacology in 2001 at the M S University, India, and was initially employed for three years in the Sun Pharma Advance research centre, India.

He completed his PhD in Pharmacology at M S University, India in 2006. He joined the School of Medicine at the University of Manchester as a Post-Doctoral Research Scientist in 2006 and worked there for 3 years. The project involved pharmacodynamic and pharmacokinetic studies of novel antimicrobial drugs.

Research interests and areas of expertise

Arvind’s expertise lies in molecular imaging using PET/CT, SPECT/CT, ultrasound, and optical imaging of preclinical disease models, and checking novel imaging biomarkers for POP /POC using in vivo studies.

Qualifications & Achievements

Imaging Physiologist (2011-Current)
Post doc Fellow, Manchester University, UK (2006-2008)
PhD in Pharmacology, M. S. University, India (2006)

Key Publications

Warn P.A., Parmar, A., Sharp, A., Majithiya, J., Denning, D. W., Efficacy of Isavuconazole, Voriconazole and Fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. Journal of Antimicrobial Chemotherapy, 63(1), 161-166. (2009)

Warn, P. A., Sharp, A., Parmar, A., Majithiya, J., Denning, D. W., Hope, W. W. Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. Antimicrobial Agents and Chemotherapy, 53(8), 3453–3461. (2009)

Yadav, M. R., Shirude, S. T., Puntambekar, D. G., Patel, P. J., Prajapati, H. B., Parmar, A., Balaraman, R., Giridhar, R. Studies in 3,4-diaryl-1,2,5-oxadiazoles and their N-oxides: Search for better COX-2 inhibitors. Acta Pharmaceutica, 57(1), 13-30. (2007)

Yadav, M. R., Nimekar, D. M., Ananthakrishnan, A., Brahmkshatriya, P. S., Shirude, S. T., Giridhar, R., Parmar, A., Balaraman, R. Synthesis of new chemical entities from paracetamol and NSAIDs with improved pharmacodynamic profile. Bioorganic & Medicinal Chemistry, 14(24), 8701-8706. (2006)

Majithiya, J. B., Parmar, A. N., Trivedi, C. J., Balaraman, R. Effect of Pioglitazone on L-NAME induced hypertension in STZ-diabetic rats. Vascular Pharmacology, 43(4), 260-266. (2005)

Majithiya, J. B., Parmar, A. N., Balaraman, R. Pioglitazone, a PPARγ agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats. Cardiovascular Research, 66(1), 150-161. (2005)

Majithiya, J. B., Parmar, A. N., Balaraman, R. Effect of curcumin on triton WR 1339 induced hypercholesterolemia in mice. Indian Journal of  Pharmacology, 36(6), 382-383. (2004)